Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 23 | 2025 | 145 | 12.190 |
Why?
|
| Surgeons | 3 | 2024 | 263 | 1.560 |
Why?
|
| Surgery, Plastic | 2 | 2020 | 43 | 1.220 |
Why?
|
| Patient Positioning | 2 | 2024 | 63 | 1.010 |
Why?
|
| Consumer Health Information | 1 | 2023 | 17 | 0.830 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 24 | 0.810 |
Why?
|
| Hemostatics | 1 | 2023 | 59 | 0.780 |
Why?
|
| Mediastinal Emphysema | 1 | 2022 | 6 | 0.780 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 41 | 0.780 |
Why?
|
| Blast Injuries | 1 | 2022 | 12 | 0.780 |
Why?
|
| Facial Nerve Injuries | 1 | 2022 | 13 | 0.780 |
Why?
|
| Facial Injuries | 1 | 2022 | 25 | 0.770 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 91 | 0.770 |
Why?
|
| Critical Care | 2 | 2024 | 398 | 0.760 |
Why?
|
| Shock, Septic | 1 | 2023 | 108 | 0.750 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2021 | 22 | 0.750 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 30 | 0.740 |
Why?
|
| Burn Units | 4 | 2023 | 21 | 0.720 |
Why?
|
| Compartment Syndromes | 1 | 2021 | 14 | 0.710 |
Why?
|
| Orbital Diseases | 1 | 2021 | 17 | 0.700 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 60 | 0.700 |
Why?
|
| Bone Nails | 1 | 2020 | 15 | 0.680 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 205 | 0.630 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 101 | 0.530 |
Why?
|
| Family Practice | 1 | 2017 | 84 | 0.530 |
Why?
|
| Humans | 28 | 2025 | 92339 | 0.530 |
Why?
|
| Mammaplasty | 1 | 2018 | 119 | 0.500 |
Why?
|
| Retrospective Studies | 11 | 2025 | 9689 | 0.490 |
Why?
|
| Emergency Medicine | 1 | 2017 | 126 | 0.490 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 259 | 0.480 |
Why?
|
| Length of Stay | 4 | 2023 | 790 | 0.460 |
Why?
|
| Referral and Consultation | 1 | 2018 | 352 | 0.460 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 505 | 0.440 |
Why?
|
| Primary Health Care | 1 | 2017 | 362 | 0.420 |
Why?
|
| Bandages | 2 | 2024 | 46 | 0.420 |
Why?
|
| Cleft Lip | 1 | 2013 | 16 | 0.410 |
Why?
|
| Cleft Palate | 1 | 2013 | 26 | 0.410 |
Why?
|
| Indians, North American | 1 | 2013 | 47 | 0.410 |
Why?
|
| Canada | 3 | 2020 | 205 | 0.400 |
Why?
|
| Hospitalization | 4 | 2023 | 925 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2017 | 807 | 0.370 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2729 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2020 | 1084 | 0.350 |
Why?
|
| Adult | 10 | 2025 | 27538 | 0.300 |
Why?
|
| Adolescent | 4 | 2023 | 9495 | 0.290 |
Why?
|
| Child | 4 | 2023 | 7309 | 0.290 |
Why?
|
| Female | 10 | 2025 | 47893 | 0.250 |
Why?
|
| Blood Loss, Surgical | 2 | 2023 | 122 | 0.240 |
Why?
|
| Male | 8 | 2025 | 43927 | 0.230 |
Why?
|
| Young Adult | 3 | 2023 | 6630 | 0.220 |
Why?
|
| Autografts | 1 | 2024 | 32 | 0.220 |
Why?
|
| Frailty | 2 | 2024 | 86 | 0.220 |
Why?
|
| Water | 2 | 2023 | 292 | 0.220 |
Why?
|
| APACHE | 1 | 2023 | 22 | 0.220 |
Why?
|
| Beverages | 1 | 2023 | 16 | 0.200 |
Why?
|
| Administration, Topical | 1 | 2023 | 97 | 0.200 |
Why?
|
| Comprehension | 1 | 2023 | 82 | 0.200 |
Why?
|
| Extremities | 1 | 2024 | 177 | 0.200 |
Why?
|
| Vasoconstrictor Agents | 1 | 2023 | 57 | 0.200 |
Why?
|
| Cheek | 1 | 2022 | 21 | 0.200 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 165 | 0.190 |
Why?
|
| United States | 4 | 2025 | 7348 | 0.190 |
Why?
|
| Hair | 1 | 2022 | 56 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1774 | 0.190 |
Why?
|
| Language | 1 | 2023 | 158 | 0.190 |
Why?
|
| Body Surface Area | 1 | 2021 | 36 | 0.190 |
Why?
|
| Research Report | 1 | 2022 | 44 | 0.180 |
Why?
|
| Internet | 1 | 2023 | 331 | 0.180 |
Why?
|
| Physical Abuse | 1 | 2020 | 5 | 0.170 |
Why?
|
| Los Angeles | 1 | 2020 | 29 | 0.170 |
Why?
|
| Hypoglycemia | 1 | 2021 | 110 | 0.170 |
Why?
|
| Resuscitation | 1 | 2021 | 111 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2024 | 391 | 0.160 |
Why?
|
| Prognosis | 3 | 2023 | 3872 | 0.160 |
Why?
|
| Middle Aged | 6 | 2025 | 27043 | 0.160 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 102 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2020 | 84 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 136 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 379 | 0.160 |
Why?
|
| Wound Healing | 1 | 2021 | 371 | 0.160 |
Why?
|
| Infant | 2 | 2023 | 3207 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2020 | 134 | 0.150 |
Why?
|
| Age Factors | 1 | 2023 | 1903 | 0.150 |
Why?
|
| Motivation | 1 | 2022 | 309 | 0.150 |
Why?
|
| Self-Injurious Behavior | 1 | 2020 | 114 | 0.140 |
Why?
|
| Esthetics | 1 | 2018 | 49 | 0.140 |
Why?
|
| Aged | 6 | 2025 | 19951 | 0.140 |
Why?
|
| Critical Illness | 1 | 2020 | 327 | 0.140 |
Why?
|
| Personnel Selection | 1 | 2018 | 62 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 81 | 0.130 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2018 | 118 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 160 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 411 | 0.130 |
Why?
|
| Self Report | 1 | 2018 | 307 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2020 | 424 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2023 | 3805 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1920 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2793 | 0.120 |
Why?
|
| General Surgery | 1 | 2018 | 238 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3776 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2020 | 2978 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2012 | 62 | 0.090 |
Why?
|
| Complementary Therapies | 1 | 2012 | 55 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6920 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3054 | 0.090 |
Why?
|
| Women's Health | 1 | 2012 | 105 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2025 | 955 | 0.080 |
Why?
|
| Rhombencephalon | 1 | 2009 | 48 | 0.080 |
Why?
|
| Risk Factors | 3 | 2025 | 5706 | 0.080 |
Why?
|
| Respiratory Center | 1 | 2009 | 55 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1298 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 319 | 0.070 |
Why?
|
| Registries | 1 | 2013 | 903 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2013 | 2506 | 0.070 |
Why?
|
| Incidence | 2 | 2025 | 1661 | 0.060 |
Why?
|
| Epinephrine | 1 | 2022 | 89 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2025 | 448 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2022 | 192 | 0.040 |
Why?
|
| Energy Intake | 1 | 2020 | 99 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 444 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 331 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 360 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 429 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 219 | 0.020 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2009 | 1 | 0.020 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2009 | 4 | 0.020 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2009 | 16 | 0.020 |
Why?
|
| 5'-Nucleotidase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 58 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2009 | 129 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 443 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2009 | 88 | 0.020 |
Why?
|
| Periodicity | 1 | 2009 | 119 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2009 | 99 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 524 | 0.020 |
Why?
|
| Respiration | 1 | 2009 | 269 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1232 | 0.020 |
Why?
|
| Adenosine | 1 | 2009 | 250 | 0.020 |
Why?
|
| Action Potentials | 1 | 2009 | 604 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 4066 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 8730 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 28053 | 0.010 |
Why?
|